The diagnostic value of SNpc using NM-MRI in Parkinson’s disease: meta-analysis
- 152 Downloads
The main purpose of this study was to systematically evaluate the accuracy of neuromelanin-sensitive magnetic resonance imaging (NM-MRI) in Parkinson’s disease (PD) diagnosis using a meta-analysis method. In PubMed, Web of Science, Embase, and Google Scholar, the literatures were searched for the diagnostic value of neuromelanin-sensitive magnetic resonance imaging in PD. The literatures were screened in the light of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Data analysis was processed by Stata 12.0 software to obtain meta-analysis, heterogeneity analysis, and publication bias. Meta-analysis results showed by using NM-MRI observed substantia nigra pars compacta (SNpc) on PD, the pooled diagnostic sensitivity and specificity were 0.82 (95% CI, 0.74–0.87) and 0.82 (95% CI, 0.73–0.89), respectively. And the pooled positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 4.58 (95% CI, 3.08–6.82) and 0.22 (95% CI, 0.16–0.31), respectively. Moreover, subgroup analysis according to the measurement criteria of SNpc showed the SNpc volume should be used as good a marker for diagnosing PD. Finally, Fagan test demonstrated that when PLR was equal to 5, the posterior probability is significantly enhanced to 53%, compared with prior probability (20%). As for NLR (0.22), the prior probability is 20%, while the posterior probability remarkably dropped to 5%. In conclusion, SNpc signal detected by NM-MRI exhibited high sensitivity and specificity for diagnosis of PD, which was a high-performance imaging diagnostic method for PD. We recommend NM-MRI imaging technology to be widely used in Parkinson’s diagnosis.
KeywordsParkinson’s disease Neuromelanin-sensitive magnetic resonance imaging (NM-MRI) Meta-analysis Diagnostic method
Compliance with ethical standards
The study was based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The searched documents are gradually screened from the title, abstract, and full text according to the pre-set inclusion exclusion criteria. The two researchers conducted the same discussion at the same time. When there is controversy, it should be judged by the third researcher.
Conflict of interests
The authors declare they have no conflict of interests.
- 7.Zucca FA, Vanna R, Cupaioli FA, Bellei C, de Palma A, di Silvestre D, Mauri P, Grassi S, Prinetti A, Casella L, Sulzer D, Zecca L (2018) Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson’s disease. NPJ Parkinsons Dis 4:17CrossRefGoogle Scholar
- 9.Pavese N. 2018 Is neuromelanin the imaging biomarker for the early diagnosis of Parkinson’s disease that we were looking for? Parkinsonism Relat Disord. Google Scholar
- 11.Zhang Z, Wang J, Chen S, Liu C, Zhang B, Peng R, Sun S, Sun X, Zhao G, Qu Q, Li Y, Zhu S, Pan X, Shao M, Wang Y (2018) Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study. Transl Neurodegener 7:32CrossRefGoogle Scholar
- 12.Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707 quiz 1837CrossRefGoogle Scholar
- 13.Tarsy D, Gordon L 2012 Clinical diagnostic criteria for Parkinson’s disease. In: Parkinson’s disease. CRC Press, 732–741Google Scholar
- 34.Reimao S, Pita Lobo P, Neutel D et al (2015) Quantitative analysis versus visual assessment of neuromelanin MR imaging for the diagnosis of Parkinson’s disease. J Park Dis 5(3):561–567Google Scholar
- 38.Ogisu K, Kudo K, Sasaki M, Sakushima K, Yabe I, Sasaki H, Terae S, Nakanishi M, Shirato H (2013) 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson’s disease. Neuroradiology 55(6):719–724CrossRefGoogle Scholar